A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma

NCT06049290 · tracked via the Priya Life Science China tracker

Sponsor

Nanjing Leads Biolabs Co.,Ltd

Phase

Phase 1/2

Started

2023-10-20

Last updated

2026-09-11

Condition(s) studied

Relapsed/Refractory Multiple Myeloma

Investigational drug(s) / intervention(s)

LBL-034 for Injection

LBL-034 for Injection: Q2W; intravenous infusion

Study summary

This trial is a single-arm, open-label, multicenter phase I/II clinical study of LBL-034 in patients with RRMM to evaluate the safety, tolerability, PK profile, immunogenicity and efficacy of LBL-034.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Agree to follow the trial treatment regimen and visit schedule, voluntarily enroll in the study, and sign the written informed consent form; 2. Age ≥ 18 years at the time of signing the informed consent; 3. Eastern Cooperative Oncology Group (ECOG) Performance Status Scale≤ 1； 4. Documentation of initial diagnosis of multiple myeloma according to IMWG diagnostic criteria,or according to the IMWG 2021 diagnostic criteria, the proportion of circulating plasma cells in peripheral blood is ≥ 5%,have documentation to diagnose PCL； 5. Have a life expectancy of at least 12 weeks； 6. Fertile men and women of childbearing age are willing to take effective contraceptive measures (including abstinence, intrauterine devices, hormonal contraception, and correct use of condoms) from the signing of the informed consent form to 6 months after the last dose of the investigational drug; women of childbearing age include premenopausal women and women who had menopause less than two years ago. Blood pregnancy test results must be negative for women of childbearing age within 7 days prior to the initial dose of the investigational drug. Exclusion Criteria: 1. Subjects who underwent major organ surgery (excluding needle biopsy) or significant trauma within 4 weeks prior to the initial use of the investigational drug,or require elective surgery during the trial period; 2. Use of immunomodulatory drugs within 14 days prior to the initial use of the investigational drug, including but not limited to thymosin, interleukin-2, and interferon； 3. Systemic use of corticosteroids or other immunosuppressants within 14 days prior to the initial use of the investigational drug;The following conditions are excluded: Treatment with topical, ocular, intra-articular, intranasal, and inhaled corticosteroids; short-term use of glucocorticoids for preventive therapy (e.g., to prevent contrast allergy); 4. Patients with active hepatitis B or C； 5. Subjects with an active infection that currently requires anti infective therapy; 6. The patient has a Medical history of immunodeficiency, including HIV antibody positive; 7. Women during pregnancy or lactation; 8. The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study.

Primary outcome measure(s)

Objective Response Rate (ORR) — From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (30 days after drug withdrawal or before the start of new anti-tumor therapy).
ORR \[including the rates of Strin-gent complete response(sCR),complete response (CR) ,Very good partial response(VGPR),and partial response (PR)\], evaluated based on the 2016 IMWG criteria(Cohorts 1, 2, and 3) and 2013 IMWG criteria(Cohort 4), refers to the percentage of study subjects who achieve a complete response or partial response. It was used to evaluate the efficacy of LBL-034 in Phase II study .
Dose-limiting toxicities（DLT） — The DLT observation period starts from the first dose until 4 weeks after the full dose first administration (including the step-up dosing period, if any).
DLT describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.DLT is defined as toxicity (possible adverse events related to LBL-034) during the DLT observation period . It was used to evaluate the safety of LBL-034 in Phase I study .
Maximum tolerated dose (MTD) — The MTD observation period starts from the first dose until 4 weeks after the full dose first administration (including the step-up dosing period, if any).
MTD is defined as the hightest dose level at which no more than 1 out of 6 subjects experiences a DLT during the first cycles. It was used to evaluate the tolerability in Phase I.
Occurrence of adverse event (AE) and serious adverse event (SAE) — From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (90 days after drug withdrawal or before the start of new anti-tumor therapy)
Adverse event (AE) will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 5.0.The safety profile of LBL-034 will be assessed by monitoring the adverse event (AE) and serious adverse event (SAE) in Phase I study.

Trial sites (21)

Facility	City	Region	Status
The First Affiliated Hospital of Wannan Medical College	Wuhu	Anhui	Recruiting
Peking University People's Hospital	Beijing	Beijing Municipality	Recruiting
The First Affiliated Hospital of Xiamen University	Xiamen	Fujian	Recruiting
Sun Yat-sen University Cancer Center	Guangzhou	Guangdong	Recruiting
Shenzhen Second People's Hospital	Shenzhen	Guangdong	Recruiting
The Afliliated Hospital of Guizhou Medical Univeristy	Guiyang	Guizhou	Recruiting
The Second Affiliated Hospital of Hainan Medical University	Haikou	Hainan	Recruiting
The First Affiliated Hospital of Henan University	Luoyang	Henan	Recruiting
Henan Cancer Hospital	Zhengzhou	Henan	Recruiting
The First Affiliated Hospital of Zhengzhou University	Zhengzhou	Henan	Recruiting
Union Hospital Tongji Medical College Huazhong University of Science and Technology	Wuhan	Hubei	Recruiting
The First Affiliated Hospital of Soochow University	Suzhou	Jiangsu	Recruiting
The First Bethune Hospital of Jilin University	Changchun	Jilin	Recruiting
Shengjing Hospital of China Medical University	Shengyang	Liaoning	Recruiting
Qingdao Municipal Hospital	Qingdao	Shandong	Recruiting
Shanghai Fourth People's Hospital	Shanghai	Shanghai Municipality	Recruiting
Shanxi Bethune Hospital	Taiyuan	Shanxi	Recruiting
The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital)	Xi’an	Shanxi	Recruiting
The First Affiliated Hospital Zhejiang University School of Medicine	Hangzhou	Zhejiang	Recruiting
The First Affiliated Hospital of Ningbo University	Ningbo	Zhejiang	Recruiting
The First Affiliated Hospital of Wenzhou Medical University	Wenzhou	Zhejiang	Recruiting

More Nanjing Leads Biolabs Co.,Ltd trials in China

A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors Recruiting

A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma Starting soon

A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] Recruiting

A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus Recruiting

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] Recruiting

Other trials for the same condition

A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma. Starting soon

A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia Recruiting

A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma Recruiting

IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia Recruiting

A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06049290 on ClinicalTrials.gov ↗ ← All trials in China